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Abstract
Fluoroquinolones are highly effective broad-spectrum antibiotics usually used for the
treatment of human and animal infections, including salmonellosis. Fluoroquinolones act
against Salmonella by inhibiting their DNA replication. However, several zoonotic sero-
types of Salmonella have developed resistance or are less susceptible to fluoroquinolones.
Salmonella presents its resistance by substituting amino acids within the topoisomerase
subunits, overexpression of multidrug efflux pumps, or decreasing the expression of outer
membrane porins. The resistance level is further increased with the plasmid-mediated
quinolone resistance genes which could horizontally transfer the resistance from strain to
strain. The development of resistance in Salmonella shows that it is a multifactorial process
and the acquisition of fluoroquinolone resistance might have significant influences on the
bacterial fitness and virulence. Due to the high level resistance against fluoroquinolones
that has been observed in Salmonella, care needs to be taken to avoid misuse and overuse
of this important class of antibiotics to minimize the occurrence and dissemination of
resistance.
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1. Introduction
Zoonotic Salmonella infections are common causes of foodborne human infections worldwide
[1]. Typhoid fever and gastroenteritis are the two main subtypes of salmonellosis. Typhoid
fever, caused by Salmonella Typhi and Paratyphi, is a generalized infection and is fatal in about
10% of cases. The symptoms are usually very severe and show serious sequel. On the other
hand, gastroenteritis is a localized infection of the gut leading to diarrhea, fever, nausea, and
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headaches and usually caused by all other zoonotic Salmonella serotypes [1, 2]. Antimicrobial
therapy is indicated in case of generalized infection with life-threatening situation. Presently,
fluoroquinolones are the drug of choice for having the high level of clinical efficacy against
most of the enteric pathogens including Salmonella [3, 4]. Probably, both human and veterinary
uses have significantly contributed to the emergence of Salmonella strains with reduced sus-
ceptibility to fluoroquinolones [5–7]. In this chapter, the updates on the development and
mechanisms of fluoroquinolone resistance in Salmonella and also the fitness and virulence
changes after acquiring resistance are introduced.
2. Resistance
2.1. Mechanism of resistance
The genetic basis of fluoroquinolone resistance in Salmonella is the mutations in DNA gyrase
(topoisomerase II) and topoisomerase IV, which are the intracellular targets of this class of
antibiotics (Figure 1) [4, 8, 9]. Other mechanisms which contribute to the resistance of Salmo-
nella to fluoroquinolone are overactivation of multidrug efflux pumps and decreased outer
membrane permeability [10, 11]. In some clinical isolates of Salmonella, plasmid-mediated
quinolone resistance (PMQR) genes also confer low-level quinolone resistance (Figure 1).
Thus, the development of fluoroquinolone resistance in Salmonella is an endpoint result of the
accumulation of several biochemical mechanisms [12].
2.1.1. Target mutations in DNA gyrase and topoisomerase IV
The quinolone resistance in Salmonella was firstly attributed to point mutations in the gyrA
gene coding for the subunit A of DNA gyrase. In Salmonella, a single-point mutation in the
quinolone resistance-determining regions (QRDRs) of the gyrA gene, which have been clus-
tered in a region of the protein between amino acids 67 and 106 [4], could mediate resistance to
nalidixic acid and decrease susceptibility to ciprofloxacin [13]; however, for higher-level resis-
tance to fluoroquinolones, the bacteria must attain additional mechanisms [14].
The most prevalent amino acid changes in nalidixic acid-resistant strains are Ser-83 (to Leu,
Thr, Phe, Tyr, or Ala) and Asp-87 (to Gly, Lys, Asn, or Tyr) [6, 15–23]. In high-level resistant
clinical S. enterica serovar Typhimurium isolates (e.g., MIC of ciprofloxacin, 32 μg/mL), double
mutations at both residues 83 and 87 have been commonly observed [24]. Other than Ser-83
and Asp-87 amino acid substitution mutations at GyrA, Salmonella strains also have mutations
at Ala-67 (to Pro), Gly-81 (to Ser, Asp, Cys, or His), and Leu-98 (to Val) (Figure 2A) [16, 18, 25].
Previously, Eaves et al. identified the mutations at Ala131 and Glu133 which are outside of the
QRDR [26] which may have different types of mechanisms conferring resistance. Different
serotypes may have different mutation positions in the gyrA gene. As reported by Giraud
et al., the substituting amino acids at Ser83 and Asp87 were not equally distributed among
different serotypes, and mutation in Asp87 prevailed in serovars Hadar and Kottbus and
mutation at Ser83 were more prevalent in serovars Newport, Virchow, and Typhimurium
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[16]. These findings were further supported by the results documented by Allen and Poppe,
who reported that all the S. Bredeney strains tested have a Ser83Tyr substitution, while all the
S. Senftenberg strains tested have a mutation of Asp87Gly [27]. The acquisition of mutations in
gyrA may play an important part in the dissemination of Salmonella of particular serotypes
[28]. The source of the strains may also be the cause of differences in the distribution of
mutations. Lindstedt et al. reported that the S. Hadar strains from Southeast Asia harbored
mutation at Ser83, while S. Hadar strains from Southern Europe and North Africa have
mutations at Asp87. They further explained that the differences might be due to the exposure
of sublethal concentrations of quinolones in East Asia and Europe/North Africa [29]. In human
strains of S. Typhimurium DT104 [22, 30] and farm animal isolates of S. Hadar and S. Monte-
video [31], Asp87Asn was the most frequently detected mutation site, while Asp87Gly as the
most common mutation in their panel of veterinary Salmonella, as reported by Piddock et al.
[21]. In contradiction to these findings, the study of Griggs et al. documented that mutation at
Ser83 is very common in veterinary isolates of S. Newport strains [18]. Strains having different
substitutions at codons 83 and/or 87 and some other additional resistance mechanisms always
show different susceptibility levels to quinolones. It might be due to the fact that sometimes
Figure 1. Mechanisms of quinolone resistance. Chromosomal mutations within the QRDRs of the genes encoding the
subunits A and B of DNA gyrase and topoisomerase IV structurally change the target protein, reducing its drug-binding
affinity. Chromosomal mutations lead to reduced outer membrane permeability and also increased expression of efflux
pumps. Plasmid-encoded quinolone-resistant genes can produce Qnr target protection proteins and AAC(60)-Ib-cr
acetyltransferase variants capable of modifying certain quinolones or QepA and OqxAB efflux pumps that actively
extrude quinolones. The global regulatory proteins MarA, SoxS, and Rob are primarily responsible for activation of acrAB
and tolC transcription.
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the same codon may have different substitutions which alter the binding capacity of
quinolones to the DNA- gyrase complex. As reported by Levy et al., during selection process
the nature of the FQ determines the gyrA mutation spectra [32]. For instance, selection with
enrofloxacin appeared more likely to select for Ser83Phe substitutions, whereas selection with
ciprofloxacin favored recovery of Asp87Gly mutants [16, 18, 22, 25, 26, 32, 33]. Levy et al.
concluded that the emergence of quinolone resistance is usually because of the mutant strains
being defective in methyl-directed mismatch repair [32].
As compared to gyrA, the mutations in gyrB, which encodes the B subunit of DNA gyrase, are
less common (Figure 2B). Point mutation at codon 463 of gyrBwith an amino acid substitution
of Ser to Tyr has been reported in a quinolone-resistant post-therapy isolate of S. enterica
serovar Typhimurium [34]. Complementation experiments provided evidence of the contribu-
tion of mutations in both gyrA and gyrB genes to the fluoroquinolone resistance [24]. For codon
Ser464, it was considered as a mild spot since it was found altered (to Phe or Tyr) in a few
independent FQ-resistant strains [33, 35–37].
The parC and parE genes of topoisomerase IV, which is the secondary target for quinolones, are
homologous gyrA and gyrB in Salmonella. Generally, the quinolone-resistant mutations in parC
occur at codon Ser80 and less frequently at codon Glu84 (Figure 2C). These codons are
homologous to the Ser83 and Asp87 codons of DNA gyrase, respectively [33, 35, 38–40].
Studies showed that mutations in parC of Salmonella do not play an important role in quinolone
Figure 2. Homology modeling and the amino acid mutations of the subunit A (A, GyrA) and subunit B (B, GyrB) of DNA
gyrase and subunit C (C, ParC) and subunit D (D, ParE) of the topoisomerase IV in Salmonella.
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resistance as mutations in gyrA or they may only be required to achieve higher-level resistance
[21, 23]. However, the experiment of transformation of parC mutants with wild-type parC
shows an associated temporary reversal resistance to ciprofloxacin in Salmonella [37]. A study
conducted by Piddock et al. reported that there are no parCmutants in 196 strains of veterinary
isolates by using a Cip MIC of ≥0.5 mg/L as a cutoff value [21]. It was further supported by the
study conducted by Giraud et al. who use in vitro and in vivo strains with Cip MICs of up to
16 mg/L [16]. Usually, mutant parC is detected in the Salmonella strains with two mutations in
gyrA, while they have been observed in E. coli with only one gyrA mutation [24, 41–43]. In
comparison to the strains without mutations, the Thr57Ser alone was able to increase the MIC
of ciprofloxacin from 6 to 11 mg/L [38]. The Thr57Ser mutation which occurs outside the
QRDR might have some different types of mechanism for quinolone resistance [29]. The
substitution of amino acids (Ser458Pro) in parE of Salmonella was detected in human isolates
from Hong Kong [38]. Mutations in ParE have been observed most rarely (Figure 2D) [44, 45].
2.1.2. Efflux pumps and porins
Different isolates may have same mutations in topoisomerases but present various quinolone-
resistant phenotypes, other mechanisms such as overexpression of efflux pumps are also
considered to contribute to the fluoroquinolone resistance [16]. Many studies have reported
the contribution of overactivation of the efflux pumps to fluoroquinolone resistance in Salmo-
nella (Figure 1) [11, 16, 40, 46].
In the past few years, many studies have been performed to investigate the role of efflux
pumps to high- and low-level resistance in Salmonella [11, 40, 47]. The fluoroquinolone
resistance level was decreased from 16- to 32-fold when the acrB gene (coding for the
transporter) and tolC gene (coding for the outer membrane component of the efflux system)
were inactivated or the AcrB efflux pump was inhibited by the inhibitor L-phenylalanine-L-
arginine-β-naphthylamine (PAβN) [11]. AcrAB-TolC efflux system appears to be the main
mechanism mediating quinolone resistance in S. Typhimurium DT104 strains with little
contribution from gyrA mutations, while in S. Typhimurium DT204, both active efflux and
accumulation of target gene mutations are required for the higher level of resistance to
fluoroquinolone [47]. In a comparative study among the S. Typhimurium with acrAB operon
mutation with its parent and AcrAB-overproducing strains, the results showed that the
AcrAB efflux pump conferred significant resistance to a number of antimicrobials [48].
Giraud et al. reported that the resistance level of S. Typhimurium strains was strongly
correlated with the expression of the AcrAB efflux pump [49]. In addition, the overexpr-
ession of efflux pumps (AcrEF and MdlAB) in a fluoroquinolone-resistant Salmonella
Typhimurium strain S21was also reported by Chen et al., but they are not contributed to the
elevation of MIC to fluoroquinolones [50]. However, another study reported that when the
AcrAB is out of function, the AcrEF can be recruited to efflux fluoroquinolones [51]. It is
generally observed that the level of the increase of the susceptibility of bacteria is dependent
on the specific FQ antibiotic used [40].
The soxRS andmarRAB operons are also present in Salmonella (Figure 1) [46, 52–56]. Recently, it
came to know that the mutations in the acrAB and acrEF operons also play an important role in
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FQ resistance. In an in vitro study conducted on FQ-resistant strain of S. Typhimurium, sub-
stitutions at amino acids Ile75 and Glu76 were described in acrR, which is the local repressor of
acrAB [57]. A study of whole genome sequencing identified a mutation of Gln78Stp on acrR in
a resistant clinical S. Choleraesuis strain with acrAB consistently overexpressed [58]. However,
the author further found that this internal stop codon in acrR was also present in susceptible
isolates, and it may be a genetic diversity in the Choleraesuis serotype rather as FQ resistance.
Some studies have shown that strains with wild-type topoisomerase genes and mar, sox, or
acrR regulatory loci, yet exhibit the low level of FQ susceptibility and overexpression of acrAB,
suggest that some other regulators may be involved. The ramA, from S. enterica serovar
Typhimurium and other enterobacteria (but is absent in E. coli), may be the regulator locus,
whose product is homologous to the acrAB transcriptional activators SoxS and MarA [59].
Experimentally, overexpression of ramA in S. Typhimurium can lead to multidrug-resistant
(MDR) phenotype, and the ramA might act by direct activation or MarA-controlled genes [60].
However, it was further reported by the authors that their MICs in 15 clinical strains were
never affected by the inactivation of ramA and finalized that ramA was not a common MDR
mechanism in Salmonella [60]. In a study by Koutsolioutsou et al. [53], during the clinical usage
of fluoroquinolones, resistant S. Typhimurium emerged with a mutation in soxRS gene, whose
overexpression leads to the increase of the resistance level [53]. Neither was marA induced
by a number of antimicrobials, salicylate did also induce marA [61]. It has been found
that the treatment of aspirin might lead to high plasma concentrations and induces MarA
overexpression [62]. Coban et al. documented that the medication of aspirin and ibuprofen
during clinical treatment of salmonellosis could lead to development of resistance [63].
It is thought that quinolones particularly hydrophilic ones penetrate the cells through porin [8].
But it is not clear yet whether the absence of OmpF has any role in decreasing the levels of
quinolone accumulation in cells. In a study by Piddock et al., the decrease or absence of OmpF
or any other OMP was not associated with the reduced accumulation of quinolones in several
strains [63]. As described by Lewin et al. and Ruiz et al., in comparison of the nalidixic acid-
resistant and acid-susceptible strains of Salmonella, no difference was found between the OMP
[23, 64], and Giraud et al. also reported that the expression level of porins in their S. Typhimurium
MAR mutants was not reduced [49]. In contradiction to the previous studies, Howard et al.
reported substantially the reduced level of OmpF expression in a S. Typhimurium strain which
was resistant to ciprofloxacin, and Toro et al. reported an isolate of S. Typhimurium that lacked
OmpF and presented MAR phenotype [65, 66].
Some previous studies reported that in quinolone-resistant Salmonella, there is an alteration in
the expression of outer membrane protein or lipopolysaccharide [17, 21, 49]. However, the role
of these alterations in decreasing the outer membrane permeability and association with
quinolone resistance is not clear. Although the role of lipopolysaccharide composition on the
accumulation of quinolones has been studied in several bacterial species, it remains unclear,
and sometimes contradictory results have been reported [67–70]. It has been assumed that in
quinolone-resistant Pseudomonas aeruginosa isolates, the amount of lipopolysaccharide
increases and forms a permeability barrier which acts preferentially against hydrophilic
quinolones [68]. The lengthening of the O-chains in the quinolone- resistant Salmonellamutants
also contributes to the reduction of permeability of the outer membrane [49].
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2.1.3. PMQRs
Transferable nalidixic acid resistance had been sought unsuccessfully in the 1970s [71], and
plasmid-mediated resistance was thought unlikely to exist since quinolones are synthetic
compounds and adequate resistance can arise by chromosomal mutations [72]. However, a
plasmid-mediated quinolone resistance (PMQR) mechanism was firstly reported by Martinez-
Martinez et al. in 1998 [73], 31 years after nalidixic acid began to be used clinically and 12 years
after modern fluoroquinolones were approved for use [74]. Presently, there are five Qnr
families which differ in sequence (QnrA, QnrB, QnrC, QnrD, and QnrS) about 40% or more
from each other [75]. In addition, the substitutions of amino acids within each family lead to
numerous variants, e.g., with more than 20 alleles, and qnrB is the most varied [75]. The first
PMQR that could transfer low-level ciprofloxacin resistance to a variety of Gram-negative
bacteria was discovered in a multiresistant urinary isolate of K. pneumoniae from Alabama.
After the responsible gene (qnr and later qnrA) was cloned and sequenced [76], qnr was soon
found at low frequency on plasmids in Gram-negative isolates around the world [77]. The
mechanism of Qnr protein is on the basis of protecting the quinolone target [4]. The qnr can
encode for a 219 amino acid protein which belongs to pentapeptide repeat family and has the
ability to bind to and protect both DNA gyrase and topoisomerase IV from fluoroquinolones
[76, 78, 79]. Structural study of a pentapeptide repeat protein from mycobacteria (MfpA) that
contributes to quinolone resistance revealed that it formed a rodlike dimer with surface charge
and dimensions similar to double-stranded DNA and could thus act as a DNA mimic [80]. The
Qnr protein might have similar structure with MfpA [80, 81], but it can only protect targets
when the concentration of quinolones is very low [76, 81, 82], and it has a glycine residue
which separates the Qnr protein into two parts. Generally, Qnr genes located on plasmids
carrying multiresistant determinants, especially those having genes encoding extended-
spectrum β-lactamases [83], e.g., qnrA and qnrB, are commonly found as a part of complex
sul1-type integrons [84].
The production of a modified aminoglycoside acetyltransferase (AAC(60)-Ib-cr) is another
mechanism of resistance to ciprofloxacin. It can modify the drug and reduce the antimicrobial
activity [85]. Based on an epidemiology study of human clinical strains, the detection fre-
quency of the aac(60)-Ib-cr gene varied from 0.4 to 34% [86] and mostly from E. coli and K.
pneumonia strains. Recently, it has been identified in Salmonella spp. isolated from chickens in
Japan and in E. coli of poultry origin in Spain or of pig origin in China [87–89]. The aac(60)-Ib-cr
gene is distributed worldwide, stable in the environment over time, and prevalent in both FQ-
susceptible and FQ-resistant isolates [90].
A conjugative plasmid with a multidrug efflux pump OqxAB was detected in clinical E. coli
strains isolated from swine, and it contributes to the resistance of olaquindox [91, 92]. Recently,
Wong and Chen [93] reported that oqxABwas found in Salmonella spp. isolated from retail meats
in Hong Kong and it confers resistance to multiple antibiotics (olaquindox quinolones and
chloramphenicol). Other isolates characterized in this study carried the qnrS and aac(60)-Ib-cr
genes. Another important plasmid-mediated efflux pump (QepA) was found in a clinical strain
of E. coli in Japan and presents MAR phenotype including aminoglycosides, fluoroquinolones,
and broad-spectrum β-lactams [94].
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PMQR genes facilitate the development of higher-level quinolone resistance and have been
detected in various bacterial species in many countries around the world [77]. A previous
study conducted on Salmonella (n = 1215) and E. coli (n = 333) isolates shows that six qnrB
variants were found in 138 qnrB-positive isolates and majority of these isolated from turkeys
[95]. Another study from Spain and Italy reported that the qnrD gene was identified in 22
Salmonella isolates of eight different serotypes [96]. A multiplex study about 107 strains of non-
Typhi Salmonella isolated in the USA from 1996 to 2003 showed that Salmonella Bovismor-
bificans carried qnrS1, qnrS2 was identified in S. Anatum, qnrB2 was reported in Salmonella
Mbandaka, and a new variant, qnrB5, was reported in seven Salmonella Berta isolates [84]. An
international collaborative study conducted in 13 European countries showed that among
isolates of Salmonella enterica of various origins (environment, food, humans, pigs, fowl, rep-
tiles, sheep, turkeys), 59% (288/485) carried PMQR genes. The qnrS1 gene was found in six
isolates with one strain bearing the aac(60)-1b-cr gene. qnrB19 and qnrD genes were found in
two and one isolates, respectively [85]. A survey conducted on 13 nalidixic acid-resistant
Salmonella spp. strains isolated from food animals in Colombia from 2004 to 2007 shows that
30.8% of the strains were positive for qnrB, while qnrB19 was found in all cases [97]. A study
performed in the Henan Province of China reported that four Salmonella enterica isolates were
slightly resistant to ciprofloxacin. These isolates were obtained from humans, and the resis-
tance was transferable by a 4.3 kb plasmid bearing the qnrD gene. It increased the MIC of
ciprofloxacin about 32-fold in E. coli [98]. The qnrD gene has been identified in 22 out of 1215
Salmonella isolates obtained from different European countries, being either of human or
animal isolates [95].
2.2. Development of resistance
The order of the implementation of different mechanisms in the process of resistance develop-
ment has attracted broad attention. The background of highly resistant isolates is not clear, and
the parent-susceptible strain cannot be obtained; thus, multiple studies have attempted to use
the in vitro multistep selections to trace the development of resistance [12]. In in vitro selection
of FQ-resistant E. coli, the first-step mutants may have a mutation in gyrA [99], the second-step
mutants show overexpression of efflux pumps and multiresistant phenotype, and the third-
step mutants present further enhanced efflux expression and more mutations in the DNA
gyrase or topoisomerase IV. In clinical isolates of E. coli, the development process seems to be
the same, and several mutations are needed for the high resistance [41, 100]. The in vitro
selection of high-level FQ-resistant Salmonella is also a multistep process [49], but the sequence
of mechanisms may be different from E. coli, where active efflux caused by the overactivation
of AcrAB efflux pump appears before mutation in the gyrA gene [49] and no mutations were
detected in parC in the third-step mutants; only the further overexpression of AcrAB efflux
pump was found.
The emergence order of each individual mechanism may somewhat depend on the particular
bacteria strains to which the antibiotic is imposed [12]. Luria-Delbruck dogma reported that
mutations may occur prior to the exposure of antimicrobials. Under the drug concentrations
within the mutant selection window (MSW), which was defined by Drlica, the bacteria with
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specific mutation can be selected [101]. In a parent-susceptible bacterial population, there may
be two types of resistant bacteria, topoisomerase mutants and efflux mutants. The number of
topoisomerase mutants is far less than the diverse efflux mutants, since only specific substitu-
tions in target topoisomerase can increase resistance and may induce fitness cost in bacteria
[102]. The efflux mutants usually mediate low-level FQ resistance; thus, for the drug concen-
trations near the bottom of the MSW, most of the selected mutants would be efflux mutants
[101]. When the drug concentration increased, the topoisomerase mutants would be selected
and become prevalent. In a treated animal, the drug concentration may be changed temporally
and spatially, so that the highly resistant strains may be easily obtained. The initial efflux
mutants facilitated the further step of selection of topoisomerase mutants. Mutations in gyrA
are frequently detected in clinical-resistant Salmonella isolates, but the sequence of the mutation
is not clear till now [16, 33]. There are also studies reported that the efflux mutations can be
induced in gyrA mutants [49]. Olliver et al. revealed that the AcrEF efflux would be activated
when the IS1 or IS10 elements were inserted in promoter regions. However, this phenomenon
was only observed in S. Typhimurium DT204, but not in S. Typhimurium phage-type DT104
[51]. The efflux mechanisms would present in specific strain according to the characteristics of
the IS elements [12].
In clinical settings, underdosing seems to be inevitable and tends to easily select for resistance
[103]. It was supported by Giraud et al., who conducted an in vivo experiment on chicken, and
the results showed that a single low dose of enrofloxacin was enough to select resistant isolates
[16]. Fluoroquinolones are usually used for population medication of sick animals by feed or
water. The variations of drug intake among each animal lead to the underdosing and selection
for resistance. In addition, the salmonellosis in swine and poultry is usually self-limited
without symptoms, when the fluoroquinolones are medicated for treating other diseases;
Salmonella is also under the antibiotic pressure and resistance selection may occur [1].
3. Fitness
Understanding the fitness effects of antimicrobial resistance evolution is crucial for controlling
the spread of resistance, as the fitness cost induced by antimicrobial resistance is one of the few
biological features of resistant organisms that can be leveraged against them [104]. The FQ
resistance in Salmonella is not as frequent as it is in other members of Enterobacteriaceae. It might
be due to the different FQ resistance mechanisms in Salmonella, which may have a prohibitive
fitness cost which restrains the spread of resistance [16, 105]. Nevertheless, the emergence and
spread of highly resistant strains were observed in the early 1990s in Europe with Salmonella
enterica serovar Typhimurium phage-type DT204 and presently reoccurred in various serovars,
such as Typhimurium, Choleraesuis, or Schwarzengrund [38, 106, 107]. This strongly stresses
the necessity of further surveillance of FQ resistance and the prudent use of FQs.
In contrast to the wealth of information available on the mechanisms leading to high-level
fluoroquinolone resistance in Salmonella, few studies to date have investigated the fitness
costs associated with this phenotype [105]. Data from these studies suggest that mutations in
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antibiotic target genes and overexpression of multidrug resistance (MDR) efflux pumps have
been associated with fitness costs, including reduced growth rates and virulence, which may
limit the survival of resistant strains in the absence of antibiotic selective pressure [108–110].
However, stabilization of resistance can occur through the development of compensatory
mutations that restore fitness without loss of the original level of resistance [111].
In vitro selected FQ-resistant Salmonella by Giraud et al. showed smaller colony size on solid
media than the susceptible counterparts [16]. Further experiments indicated that FQ-resistant
mutants selected in vitro or in vivo (chicken) varied dramatically in the level of resistance to
FQs and the growth characteristics in culture medium and in chickens in the absence of FQ
antimicrobials. The in vitro selected mutants were highly resistant to FQs, showed significantly
reduced growth rate in culture medium, and could not colonize chickens. In contrast, the
in vivo selected resistant isolates exhibited intermediate susceptibility to FQs, had normal
growth in liquid medium (slow growth on solid medium), and were able to colonize chickens
at the extent comparable to or lower than that of the wild-type strains [105]. The fitness was
restored partly after several passages in vitro or in vivowithout antibiotics [105]. Another study
described the fitness costs associated with high-level fluoroquinolone resistance for phenotyp-
ically and genotypically characterized ciprofloxacin-resistant Salmonella enterica serotype
Enteritidis mutants (104-cip and 5408-cip, MIC >32 g/ml) [112]. Mutants 104-cip and 5408-cip
displayed altered morphology on agar and by electron microscopy, reduced growth rates,
motility and invasiveness in Caco-2 cells, and increased sensitivity to environmental stresses.
Microarray data revealed decreased expression of virulence and motility genes in both
mutants. Reverted clones for mutant 104-cip were obtained from separate lineages after sev-
eral passages on antibiotic-free agar. All fitness costs, except motility, were reversed in the
reverted strains. The altered porin and lipopolysaccharide (LPS) profiles observed in 104-cip
were reversed, and additional mutations in SoxR and ParC were observed in the reverted
strain. Randall et al. reported that the disinfectant-exposed S. Typhimurium strains, although
MAR, were less fit, were less able to disseminate than the parent strain, and were not prefer-
entially selected by therapeutic antibiotic treatment [113].
However, using in vitro competition experiments, Baker et al. assayed the fitness of 11 isogenic
S. Typhimurium strains with resistance mutations in the FQ target genes, gyrA and parC [104].
The results showed that in the absence of antimicrobial pressure, 6 out of 11 mutants carried a
selective advantage over the antimicrobial-sensitive parent strain, indicating that FQ resistance
in S. Typhimurium is not typically associated with fitness costs. Double mutants exhibited
higher expected fitness cost as a result of synergistic epistasis, signifying that epistasis may be
a critical factor in the evolution and molecular epidemiology of S. Typhimurium.
The measurement of fitness can also be influenced by a number of factors. In classical compe-
tition assays [114, 115], antimicrobial-susceptible and antimicrobial-resistant organisms are
competed over many generations, and their sensitivity and resistance are noted at various
stages; hence, the fitness of the resistant strain to the sensitive strain can be calculated from
the population trajectories [116–118]. For competitive growth assay, the selection of relative
strain is critically important [119, 120]. It would be difficult to measure the effect of a specific
mutation when using imperfectly isogenic strains [112, 117, 121, 122]. The enumeration and
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culturing of bacteria may also be inaccurate due to the spontaneous mutations after exposed to
low concentrations of antibiotics. Usually, S. Typhimurium disseminate through the macro-
phages after invading the intestinal epithelial cells (M cells). Intracellular assay using epithelial
cell or macrophage as models can provide a suitable method for measuring fitness in S. Typhi
[123]. Nevertheless, the antibiotic exposure, uptake, and cellular replication and division
would affect the experimental accuracy and reproducibility. The in vivo competition experi-
ment using animals as models is a well-described method. But it is hard to control the brief
duration of infection, which may result in small variations in bacterial numbers and genera-
tions [104].
4. Virulence
There is an increase in the knowledge about the virulence mechanisms of Salmonellawhich led to
a broad study of the Salmonella pathogenicity islands (SPIs) [124, 125] and other virulence deter-
minants, such as virulence plasmid, adhesins, flagella, and biofilm-related proteins [126–130].
These virulence factors are controlled by an extensively complicated regulatory system, which
correlates and synchronizes all the elements [131].
Several studies have investigated the impact of acquisition of fluoroquinolone resistance on the
virulence of Salmonella. In a classical study by Bjorkman et al. investigating the virulence of
nalidixic acid-resistant strain of Salmonella Typhimurium, they found that the virulence was
reduced after acquiring resistance, but compensatory mutations occurred rapidly to restore the
virulence without losing the resistance [132]. Other studies showed that the acrB gene [133]
and tolC gene [8] may associate with virulence in Salmonella. The acrB mutant showed a
reduced ability to colonize the intestine of mice. The tolC mutant was a virulent factor for mice
when administered by the oral route. Fabrega et al. [134] documented that the activation of
efflux, production of biofilm, and bacterial fitness are interrelated. The FQ resistance was
linked to the reduction of biofilm production and decreased expression of csgB gene. Giraud
et al. [135] reported that the ramRA mutations may reduce the invasiveness ability of clinical
FQ-resistant S. Typhimurium strains, but this is strain-dependent. In a registry-based cohort
study performed by Helms et al. [136], in comparison with infections by pansusceptible
strains, the infections with FQ-resistant S. Typhimurium was associated with a 3.15-fold higher
risk of invasive illness or death within 90 days of infection.
5. Conclusions
Fluoroquinolones are one of the most valuable antibiotics used for the treatment of a variety of
infections in both humans and animals, especially salmonellosis. However, the usage has led to
the prevalence of FQ resistance among different serotypes of Salmonella, and ultimately the
clinical efficacy has been compromised. To preserve the efficiency of fluoroquinolones, the drugs
should be used prudently, the residues in foods need to be monitored, and comprehensive
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surveillance should be implemented to the resistance of bacteria from both animals and humans.
Efflux pump inhibitors can be applied as new therapeutics and combined with fluoroquinolones
to minimize the emergence of high-level resistance in different pathogens, including Salmonella.
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